Jorge Aguilera Sáez
Barcelona, 08035, Spain
NCT Number: NCT04558944
A prospective, randomized, controlled study. The patients were divided into two groups with twenty patients per group. The control group received the standard treatment for postburn scars. The treatment group received the standard treatment and treatment of postburn scars with Extracorporeal Shock Wave Therapy 512 impulses of 0.15mJ/mm 2 in each session, twice per week for 4 weeks.
The investigators assessed the appearance of scar with the Vancouver Scar Scale (VSS), pruritus and pain with Visual Analog Scale (VAS) before the start of the treatment and at 2 weeks and 5 months after the treatment.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Barcelona, 08035, Spain
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Acoustic high amplitude waves with Energy Flux Density of 0.15mJ/mm 2 and 512 pulses per session. A total of two sessions per week during a 4-week period.
Time frame: 6 months from inclusion
Scar appearance by Vancouver Scar Scale. Minimum value 0. Maximum value 13. Higher scores mean a worse outcome.
Time frame: 6 months from inclusion
Pruritus measured by Visual Analogue Scale. Minimum value 0. Maximum value 10. Higher scores mean a worse outcome.
Time frame: 6 months from inclusion
Pain measured by Visual Analogue Scale. Minimum value 0. Maximum value 10. Higher scores mean a worse outcome.
Hospital Universitari Vall d'Hebron Research Institute
Other
Clinical Use of the Extracorporeal Shock Wave Therapy in the Treatment of Pathological Post Burn Scars
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01789346
Cicatrix, Cicatrix, Hypertrophic
Washington D.C., District of Columbia, United States
View Trial DetailsNCT03366194
Cicatrix, Cicatrix, Hypertrophic
Scottsdale, Arizona, United States
View Trial DetailsNCT02707627
Burns, Cicatrix
Toronto, Ontario, Canada
View Trial DetailsNCT03569267
Cicatrix, Cicatrix, Hypertrophic
Leeds, United Kingdom
View Trial Details